Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





TB-Related Articles										Related Pages
										Return to Main MenuAboukheir MK, Alvarado-Ramy F, Fernandez Vazquez M, Joglar O. Notes from the Field: Tuberculosis Control in the Aftermath of Hurricane Maria – Puerto Rico, 2017. MMWR Morb Mortal Wkly Rep.external icon 2019 Jan 18;68(2):46-47. doi: 10.15585/mmwr.mm6802a6. PMID: 30653488.
Agizew T, Boyd R, Auld AF, Payton L, Pals SL, Lekone P, Chihota V, Finlay A. Treatment outcomes, diagnostic and therapeutic impact: Xpert vs. smear. A systematic review and meta-analysis.external icon Int J Tuberc Lung Dis. 2019 Jan 1;23(1):82-92. doi: 10.5588/ijtld.18.0203. PMID:30674379.
Agizew T, Chihota V, Nyirenda S, Tedla Z, Auld AF, Mathebula U, Mathoma A, Boyd R, Date A, Pals SL, Lekone P, Finlay A. Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial. BMC Infect Dis.external icon 2019 Dec 16;19(1):1058. doi: 10.1186/s12879-019-4697-5. PMID: 31842773.Year202120202019201820172016201520142013Armstrong GL, MacCannell DR, Taylor J, Carleton HA, Neuhaus EB, Bradbury RS, Posey JE, Gwinn M. Pathogen Genomics in Public Health. external iconN Engl J Med. 2019 Dec 26;381(26):2569-2580. doi: 10.1056/NEJMsr1813907. PMID: 31881145.
Armstrong LR, Winston CA, Stewart B, Tsang CA, Langer AJ, Navin TR. Changes in tuberculosis epidemiology, United States, 1993-2017. Int J Tuberc Lung Dis.external icon 2019 Jul 1;23(7):797-804. doi: 10.5588/ijtld.18.0757. PMID: 31439110.
Bardenheier BH, Pavkov ME, Winston CA, Klosovsky A, Yen C, Benoit S, Gravenstein S, Posey DL, Phares CR. Prevalence of Tuberculosis Disease Among Adult US-Bound Refugees with Chronic Kidney Disease.external icon J Immigr Minor Health. 2019 Jan 5. doi: 10.1007/s10903-018-00852-8. [Epub ahead of print]. PMID: 30612283.
Belanger A, Morris SB, Brostrom R, Yost D, Goswami N, Oxtoby M, Moore M, Westenhouse J, Barry PM, Shah NS. Introduction and evaluation of multidrug-resistant tuberculosis supplemental surveillance in the United States.external icon J Clin Tuberc Other Mycobact Dis. 2019;15:100090.
Bonney W, Price SF, Miramontes R. Design and Implementation of Data Exchange Formats for Molecular Detection of Drug-Resistant Tuberculosis.external icon AMIA Jt Summits Transl Sci Proc. 2019 May 6;2019:686-695. eCollection 2019. PMID: 31259025.
Centers for Disease Control and Prevention. Nationwide Shortage of Tuberculin Skin Test Antigens: CDC Recommendations for Patient Care and Public Health Practice. MMWR Morb Mortal Wkly Rep.external icon 2019 Jun 21;68(24):552-553. doi: 10.15585/mmwr.mm6824a4. PMID: 31220054.
Cowger TL, Wortham JM, Burton DC. Epidemiology of tuberculosis among children and adolescents in the USA, 2007-17: An analysis of national surveillance data. Lancet Public Health.external icon 2019 Oct;4(10):e506-e516. doi: 10.1016/S2468-2667(19)30134-3. Epub 2019 Aug 21. PMID: 31446052.
de Vos M, Ley SD, Wiggins KB, Derendinger B, Dippenaar A, Grobbelaar M, Reuter A, Dolby T, Burns S, Schito M, Engelthaler DM, Metcalfe J, Theron G, van Rie A, Posey J, Warren R, Cox H. Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment.external icon N Engl J Med. 2019 May 30;380(22):2178-2180. doi: 10.1056/NEJMc1815121. No abstract available. PMID: 31141643.
Dirlikov E, Thomas D, Yost D, Tejada-Vera B, Bermudez M, Joglar O, Chorba T. Tuberculosis Surveillance and Control, Puerto Rico, 1898–2015. Emerg Infect Dis. 2019;25(3):538-546. doi:10.3201/eid2503.181157.
Goodell AJ, Shete PB, Vreman R, McCabe D, Porco TC, Barry PM, Flood J, Marks SM, Hill A, Cattamanchi A, Kahn JG. Outlook for tuberculosis elimination in California: An individual-based stochastic model.external icon PLoS One. 2019 Apr 9;14(4):e0214532. doi: 10.1371/journal.pone.0214532. eCollection 2019. PMID: 30964878.
Goswami ND, Mase S, Griffith D, Bhavaraju R, Lardizabal A, Lauzardo M, Chen L, Wilson J, Chappelle C, Haley CA. Tuberculosis in the United States: Medical Consultation Services Provided by 5 Tuberculosis Regional Training and Medical Consultation Centers, 2013-2017.external icon Open Forum Infect Dis. 2019 Apr 4;6(6):ofz167. doi: 10.1093/ofid/ofz167. eCollection 2019 Jun. PMID: 31205971.
Haddad MB, Lash TL, Hill AN, Navin TR, Castro KG, Gandhi NR, Winston CA. Robustness of NHANES Estimates of the U.S. Prevalence of a Positive Tuberculin Skin Test.external icon Epidemiology. 2019 Nov 14. doi: 10.1097/EDE.0000000000001141. [Epub ahead of print]. PMID: 31764278.
Haddad MB, Raz KM, Hill AN, Navin TR, Castro KG, Winston CA, Gandhi NR, Lash TL. Influence of County Sampling on Past Estimates of Latent Tuberculosis Infection Prevalence.external icon Ann Am Thorac Soc. 2019 Mar 19. doi: 10.1513/AnnalsATS.201901-062RL. PMID: 30888833.
Hedges KNC, Borisov AS, Saukkonen JJ, Scott NA, Hecker EJ, Bozeman L, Dukes Hamilton C, Kerrigan A, Bessler P, Moreno-Martinez A, Arevalo B, Goldberg SV. Nonparticipation reasons in a randomized international trial of a new latent tuberculosis infection regimen.external icon Clin Trials. 2019 Nov 6:1740774519885380. doi: 10.1177/1740774519885380. [Epub ahead of print]. PMID: 31690107.
Holland DP, Alexander S, Onwubiko U, Goswami ND, Yamin A, Mohamed O, Sales RM, Grant G, Talboy P, Ray S, Toomey KE. Response to Isoniazid-Resistant Tuberculosis in Homeless Shelters, Georgia, USA, 2015-2017.external icon Emerg Infect Dis. 2019 Mar;25(3):593-595. doi: 10.3201/eid2503.181678. PMID: 30789335.
Imada EK, Roberson EK, Goswami ND, Brostrom RJ, Moser K, Tardivel K. Notes from the Field: Meningeal and Pulmonary Tuberculosis on a Commercial Fishing Vessel – Hawaii, 2017. MMWR Morb Mortal Wkly Rep.external icon 2019 Jun 21;68(24):554-555. doi: 10.15585/mmwr.mm6824a5. PMID: 31220056.
Iqbal SA, Armstrong LR, Kammerer JS, Truman BI. Risk Factors for and Trends in Isoniazid Monoresistance at Diagnosis of Tuberculosis-United States, 1993-2016.external icon J Public Health Manag Pract. 2019 Oct 31. doi: 10.1097/PHH.0000000000001060. [Epub ahead of print]. PMID: 31688735.
Iqbal SA, Isenhour CJ, Mazurek G, Langer AJ, Chang MH, Truman BI. Factors Associated With Latent Tuberculosis Infection Treatment Failure Among Patients With Commercial Health Insurance-United States, 2005-2016.external icon J Public Health Manag Pract. 2019 Oct 31. doi: 10.1097/PHH.0000000000001077. [Epub ahead of print]. PMID: 31688742.
Lam CK, Fluegge K, Macaraig M, Burzynski J. Cost savings associated with video directly observed therapy for treatment of tuberculosis. Int J Tuberc Lung Dis.external icon 2019 Nov 1;23(11):1149-1154. doi: 10.5588/ijtld.18.0625. PMID: 31718750.
Langer AJ, Navin TR, Winston CA, LoBue P. Epidemiology of Tuberculosis in the United States.external icon Clin Chest Med. 2019 Dec;40(4):693-702. doi: 10.1016/j.ccm.2019.07.001. Review. PMID: 31731978.
Lienhardt C, Vernon AA, Cavaleri M, Nambiar S, Nahid P. Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance. PLoS Med.external icon 2019 Sep 6;16(9):e1002915. doi: 10.1371/journal.pmed.1002915. eCollection 2019 Sep. PMID: 31490921.
Lo TQ, Matlhare L, Mugisha K, Lere TD, Ho-Foster A, Boyd R, Cavanaugh J, Ncube R, Steenhoff AP, Arscott-Mills T. Initiation of anti-tuberculosis treatment in children following gastric aspirate testing, Botswana, 2008-2012.external icon Int J Tuberc Lung Dis. 2019 Mar 1;23(3):315-321. doi: 10.5588/ijtld.18.0404. PMID: 30871662.
Mahoney D, Chorba T. Romanticism, Mycobacterium, and the Myth of the Muse. Emerg Infect Dis. 2019;25(3):617-618. doi:10.3201/eid2503.ac2503.
Marks SM, Katz DJ, Davidow AL, Pagaoa MA, Teeter LD, Graviss EA. The Impact of HIV Infection on TB Disparities Among US-Born Black and White Tuberculosis Patients in the United States.external icon J Public Health Manag Pract. 2019 Feb 14. doi: 10.1097/PHH.0000000000000949. [Epub ahead of print]. PMID:30789591.
Marks SM, Woodruff RY, Owusu-Edusei K, Asay GRB, Hill AN. Estimates of Testing for Latent Tuberculosis Infection and Cost, United States, 2013. Public Health Rep.external icon 2019 Sep/Oct;134(5):522-527. doi: 10.1177/0033354919862688. Epub 2019 Jul 24. PMID: 31339816.
Mase S, Chorba T, Parks S, Belanger A, Dworkin F, Seaworth B, Warkentin J, Barry P, Shah N. Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis in the United States.external icon Clin Infect Dis. 2019 Sep 26. pii: ciz914. doi: 10.1093/cid/ciz914. [Epub ahead of print]. PMID: 31556947.
Mase SR, Chorba T. Treatment of Drug-Resistant Tuberculosis.external icon Clin Chest Med. 2019 Dec;40(4):775-795. doi: 10.1016/j.ccm.2019.08.002. Review. PMID: 31731984.
Mase SR, Samron R, Ashkin D, Castro KG, Ryan S, Seaworth B, Chen L, Lardizabal A, Tuckey D, Khan A, Posey DL, Chappelle C, Temesgen Z. Tuberculosis Regional Training and Medical Consultation Centers in the United States: Characteristics, outcomes, and quality of medical consultations, June 1, 2010 – May 31, 2014. J Clin Tuberc Other Mycobact Dis.external icon 2019 Jul 2;17:100114. doi: 10.1016/j.jctube.2019.100114. eCollection 2019 Dec. PMID: 31788557.
Menzies NA, Parriott A, Shrestha S, Dowdy DW, Cohen T, Salomon JA, Marks SM, Hill AN, Winston CA, Asay G, Barry P, Readhead A, Flood J, Kahn JG, Shete PB. Comparative Modelling of Tuberculosis Epidemiology and Policy Outcomes in California.external icon Am J Respir Crit Care Med. 2019 Oct 18. doi: 10.1164/rccm.201907-1289OC. [Epub ahead of print]. PMID: 31626560.
Miller AP, Malekinejad M, Horváth H, Blodgett JC, Kahn JG, Marks SM. Healthcare facility-based strategies to improve tuberculosis testing and linkage to care in non-U.S.-born population in the United States: A systematic review.external icon PLoS One. 2019 Sep 30;14(9):e0223077. doi: 10.1371/journal.pone.0223077. eCollection 2019. PMID: 31568507.
Mongkolrattanothai T, Lambert LA, Winston CA. Tuberculosis among healthcare personnel, United States, 2010-2016. Infect Control Hosp Epidemiol.external icon 2019 Jun;40(6):701-704. doi: 10.1017/ice.2019.76. Epub 2019 Apr 23. PMID: 31012401.
Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR Jr, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med.external icon 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST. PMID: 31729908.
Nwana N, Marks SM, Lan E, Chang AH, Holcombe M, Morris SB. Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness.external icon PLoS One. 2019 Mar 13;14(3):e0213524. doi: 10.1371/journal.pone.0213524. eCollection 2019. PMID: 30865724.
Pratt RH, Manangan LP, Cummings CN, Langer AJ. Noncountable Tuberculosis Case Reporting, National Tuberculosis Surveillance System, United States, 2010-2014. Public Health Rep.external icon 2020 Jan;135(1):18-24. doi: 10.1177/0033354919884302. Epub 2019 Nov 13. PMID: 31722186.
Reichler MR, Khan A, Sterling TR, Zhao H, Chen B, Yuan Y, Moran J, McAuley J, Mangura B; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk Factors for Tuberculosis and Effect of Preventive Therapy Among Close Contacts of Persons with Infectious Tuberculosis.external icon Clin Infect Dis. 2019 May 24. pii: ciz438. doi: 10.1093/cid/ciz438. [Epub ahead of print]. PMID: 31127813.
Sable SB, Posey JE, Scriba TJ. Tuberculosis Vaccine Development: Progress in Clinical Evaluation.external icon. Clin Microbiol Rev. 2019 Oct 30;33(1). pii: e00100-19. doi: 10.1128/CMR.00100-19. Print 2019 Dec 18. Review. PMID: 31666281.
Schmit KM, Brostrom R, Largen A, Pyan A, Wang Z, Mase S, Morris S. Higher Rates of Tuberculosis Among Class B1 Filipino Immigrants to Hawaii Compared to Nationwide, 2010-2014.external icon J Immigr Minor Health. 2019. Feb 26. doi: 10.1007/s10903-019-00855-z. [Epub ahead of print]. PMID: 30806953.
Sharling L, Marks SM, Goodman M, Chorba T, Mase S. Rifampin-Resistant Tuberculosis In The United States, 1998-2014.external icon Clin Infect Dis. 2019 Jun 22. pii: ciz491. doi: 10.1093/cid/ciz491. [Epub ahead of print]. PMID: 31233131.
Shrestha S, Cherng S, Hill AN, Reynolds S, Flood J, Barry PM, Readhead A, Oxtoby M, Lauzardo M, Privett T, Marks SM, Dowdy DW. Impact and Effectiveness of State-level Tuberculosis interventions in California, Florida, New York and Texas: A model-based analysis.external icon Am J Epidemiol. 2019 Jun 28. pii: kwz147. doi: 10.1093/aje/kwz147. [Epub ahead of print]. PMID: 31251797.
Sosa LE, Njie GJ, Lobato MN, Bamrah Morris S, Buchta W, Casey ML, Goswami ND, Gruden M, Hurst BJ, Khan AR, Kuhar DT, Lewinsohn DM, Mathew TA, Mazurek GH, Reves R, Paulos L, Thanassi W, Will L, Belknap R. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep. 2019 May 17;68(19):439-443. doi: 10.15585/mmwr.mm6819a3. PMID:
31099768.
Talwar A, Tsang, CA, Price SF, Pratt RH, Walker WL, Schmit KM, Langer AJ. Tuberculosis — United States, 2018. MMWR Morb Mortal Wkly Rep. 2019 March 22; 68(11);257–262.
Tornheim JA, Starks AM, Rodwell TC, Gardy JL, Walker TM, Cirillo DM, Jayashankar L, Miotto P, Zignol M, Schito M. Building the framework for standardized clinical laboratory reporting of next generation sequencing data for resistance-associated mutations in Mycobacterium tuberculosis complex.external icon Clin Infect Dis. 2019 Mar 18. pii: ciz219. doi: 10.1093/cid/ciz219. [Epub ahead of print]. PMID: 30883637.
Tsang CA, Shah N, Armstrong LR, Marks SM. Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.external icon Clin Infect Dis. 2019 Apr 4. pii: ciz263. doi: 10.1093/cid/ciz263. [Epub ahead of print]. PMID: 30944927.
Venkatappa TK, Punnoose R, Katz DJ, Higgins MP, Banaei N, Graviss EA, Belknap RW, Ho CS. Comparing QuantiFERON-TB Gold Plus with Other Tests To Diagnose Mycobacterium tuberculosis Infection. J Clin Microbiol.external icon 2019 Oct 23;57(11). pii: e00985-19. doi: 10.1128/JCM.00985-19. Print 2019 Nov. PMID: 31462550.
Vernon A, Bishai W. Modelling Treatment of Latent TB: Shortening the Leap of Faith?external icon Am J Respir Crit Care Med. 2019 Nov 25. doi: 10.1164/rccm.201911-2160ED. [Epub ahead of print]. PMID: 31765598.
Vonnahme L, Haddad MB, Navin TR. Factoring Prior Treatment into Tuberculosis Infection Prevalence Estimates, United States, 2011-2012 external icon. Emerg Infect Dis 2019; 25(10): 1949–1951. doi: 10.3201/eid2510.190439. PMID: 31538921.
Wansaula Z, Wortham JM, Mindra G, Haddad MB, Salinas JL, Ashkin D, Morris SB, Grant GB, Ghosh S, Langer AJ. Bacillus Calmette-Guérin Cases Reported to the National Tuberculosis Surveillance System, United States, 2004-2015. Emerg Infect Dis.external icon 2019 Mar;25(3):451-456. doi: 10.3201/eid2503.180686. PMID: 30789145.
Wilson JW, Nilsen DM, Marks SM. Multidrug Resistant Tuberculosis in Patients with HIV: Management Considerations within High-Resourced Settings. Ann Am Thorac Soc.external icon 2019 Jul 31. doi: 10.1513/AnnalsATS.201902-185CME. [Epub ahead of print]. PMID: 31365831.
Zimba O, Tamuhla T, Basotli J, Letsibogo G, Pals S, Mathebula U, Mathoma A, Serumola C, Ramogale K, Boyd R, Tran T, Finlay A, Auld A, Date A, Alexander H, Chihota V, Agizew T. The effect of sputum quality and volume on the yield of bacteriologically-confirmed TB by Xpert MTB/RIF and smear.external icon Pan Afr Med J. 2019 Jun 13;33:110. doi: 10.11604/pamj.2019.33.110.15319. eCollection 2019. PMID: 31489088.
							
					
						Page last reviewed:  March 2, 2020										Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue